NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, raised $165 million by offering 7.5 million shares (all primary) at $22, below the downwardly revised range of $23 to $24. The company originally planned to offer 12.5 million shares, including 5 million secondary shares, at $26 to $29. NovoCure plans to list on the Nasdaq under the symbol NVCR. J.P. Morgan, Deutsche Bank and Evercore Partners acted as lead managers on the deal.
